An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
Recruiting · NCT07459686 · Observational (researchers observe without assigning treatment) · Lead sponsor: Pfizer
View the official record on ClinicalTrials.gov →Interventions studied
Velsipity
What this trial is about
A study to assess the safety and effectiveness of Velsipity Tablets 2 mg during long-term treatment (up to a maximum of 52 weeks) in patients with ulcerative colitis under actual medical practice.
Who can take part
Age range
0 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- to be eligible for inclusion in the study:
- Patients with moderate to severe ulcerative colitis for whom treatment with this drug was started for the first time after the contract date for this study. Patients who have participated in a clinical study of this drug in the past or patients who have participated in this study are excluded.
- Patients who understand the contents of this study and give consent to provision of the information collected in this study to third parties and the use of it for other purposes.
Where it is running
1 location listed.
- Pfizer - Tokyo, Japan